Scienion
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|---|
EBITDA | - | - | - | 3.6m | 5.0m | (<1m) | 4.4m |
Profit | 1.8m | 1.7m | <1m | 3.0m | 3.3m | (1.4m) | 3.2m |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
€4.5m | Secondary | ||
€150k | Grant | ||
€80.0m Valuation: €80.0m 16.1x EV/LTM EBITDA | Acquisition | ||
Total Funding | €150k |
Recent News about Scienion
EditSCIENION specializes in high precision dispensing and single cell isolation technologies, catering to the life sciences and diagnostic industries. The company offers a comprehensive product portfolio that includes ultra-low volume dispensing systems, single cell isolation technologies, and multiplex sample analysis tools. SCIENION's solutions are utilized by leaders in various sectors for applications such as cell line development, single cell sequencing, and diagnostic test manufacturing. The company operates on a B2B model, serving clients who require customized, high-precision solutions for their research and development needs. Revenue is generated through the sale of specialized equipment, customized solutions, and ongoing customer support services. SCIENION is ISO 9001:2015 certified, ensuring high-quality standards and reliability. The company also invests significantly in R&D to advance cost-efficient next-generation diagnostic platforms.
Keywords: high precision dispensing, single cell isolation, diagnostic test manufacturing, life sciences, multiplex analysis, ultra-low volume, cell line development, single cell sequencing, ISO 9001:2015, R&D investment.